Table 3.
Baseline and follow-up data of patients on colchicine alone (n = 7) and ULT (n = 92)
| Colchicine group |
ULT and colchicine group |
|||||||
|---|---|---|---|---|---|---|---|---|
| SF-36 | Baseline mean (s.d.) | 1-year mean (s.d.) | Baseline-12 month, mean (s.d.) | Effect size | Baseline mean (s.d.) | 1-year mean (s.d.) | Baseline-12 month, mean (s.d.) | Effect size |
| Physical function | 47.41 (6.53) | 50.42 (6.01) | 3.01 (4.68) | 0.46 | 43.08 (11.24) | 48.24 (8.96) | 5.53 (9.35)* | 0.49 |
| Role physical | 49.51 (11.57) | 50.21 (14.61) | 0.7 (6.28) | 0.06 | 43.24 (11.34) | 49.37 (10.04) | 6.23 (11.66)* | 0.55 |
| Bodily pain | 52.46 (12.09) | 58.01 (10.86) | 5.55 (6.4) | 0.46 | 38.95 (10.63) | 51.53 (10.66) | 12.87 (12.96)* | 1.21 |
| General health | 48.23 (8.01) | 50.89 (5.23) | 2.66 (7.14) | 0.33 | 42.63 (8.9) | 46.74 (9.24) | 4.57 (8.01)* | 0.51 |
| Vitality | 62.79 (8.43) | 61.46 (5.7) | −1.34 (8.62) | −0.16 | 49.8 (12.02) | 54.32 (11.43) | 4.34 (9.98)* | 0.36 |
| Social functioning | 55.29 (4.12) | 53.73 (6.18) | −1.56 (2.66) | −0.38 | 44.74 (11.97) | 50.93 (9.04) | 5.38 (11.39)* | 0.45 |
| Role emotional | 51.44 (8.52) | 55.88 (0) | 4.44 (8.52) | 0.52 | 48.79 (11.23) | 51.27 (9.01) | 1.94 (10.33) | 0.17 |
| Mental health | 56.85 (9.18) | 58.86 (9.26) | 2.01 (11.35) | 0.22 | 49.18 (11.97) | 52.32 (10.5) | 2.61 (9)* | 0.22 |
| SF-36 PCS | 47.61 (8.61) | 50.23 (11.1) | 2.62 (4.34) | 0.3 | 39.8 (9.32) | 48.3 (8.72) | 9.19 (9.83)* | 0.99 |
| SF-36 MCS | 58.83 (5.01) | 59.64 (6.27) | 0.81 (8.36) | 0.16 | 51.63 (10.97) | 53.59 (9.41) | 0.93 (9.01) | 0.08 |
None of the comparisons was significant for the colchicine group. *P < 0.05.